Geode Capital Management increased its stake in Corcept Therapeutics, while Morgan Stanley lifted its holdings and Renaissance Technologies trimmed its position.
2 reports, 1 independent
Updated Aug 5
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Geode Capital Management increased its stake in Corcept Therapeutics, while Morgan Stanley lifted its holdings and Renaissance Technologies trimmed its position.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
Nothing else this week.
-
Geode Capital Management
American Investment Management firm based in Boston, Massachusetts
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
-
Renaissance Technologies
American hedge fund firm
Related events
- Corcept Therapeutics and Halozyme Therapeutics are identified as top holdings in specific U.S. small-cap ETFs.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
- Renaissance Technologies increased holdings while Benchmark, Citigroup, and Morgan Stanley issued rating updates on October 14, 2026.
Coverage
Newest first; wire copies grouped- themarketsdaily.comCorcept Therapeutics Incorporated $CORT Shares Sold by Renaissance Technologies LLC